Asthma devices – what pharmacists should know
- At: 2013 FIP Congress in Dublin (Ireland)
- Type: Presentation
- By: LUNDBäCK, Hans (AstraZeneca, Pharmaceutical Development, Mölndal, Sweden)
It is obvious from clinical studies reported in the literature that inhaler therapy with respect to asthma control and COPD outcomes is sub-optimal in clinical practice compared to the controlled situation in clinical trials. There are surely numerous of reasons to this discrepancy, but the primary cause is probably poor inhaler device handling.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.